Cargando…

Curcumin Formulations and Trials: What’s New in Neurological Diseases

Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliardi, Stella, Morasso, Carlo, Stivaktakis, Polychronis, Pandini, Cecilia, Tinelli, Veronica, Tsatsakis, Aristides, Prosperi, Davide, Hickey, Miriam, Corsi, Fabio, Cereda, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698610/
https://www.ncbi.nlm.nih.gov/pubmed/33217959
http://dx.doi.org/10.3390/molecules25225389
_version_ 1783615871267110912
author Gagliardi, Stella
Morasso, Carlo
Stivaktakis, Polychronis
Pandini, Cecilia
Tinelli, Veronica
Tsatsakis, Aristides
Prosperi, Davide
Hickey, Miriam
Corsi, Fabio
Cereda, Cristina
author_facet Gagliardi, Stella
Morasso, Carlo
Stivaktakis, Polychronis
Pandini, Cecilia
Tinelli, Veronica
Tsatsakis, Aristides
Prosperi, Davide
Hickey, Miriam
Corsi, Fabio
Cereda, Cristina
author_sort Gagliardi, Stella
collection PubMed
description Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.
format Online
Article
Text
id pubmed-7698610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76986102020-11-29 Curcumin Formulations and Trials: What’s New in Neurological Diseases Gagliardi, Stella Morasso, Carlo Stivaktakis, Polychronis Pandini, Cecilia Tinelli, Veronica Tsatsakis, Aristides Prosperi, Davide Hickey, Miriam Corsi, Fabio Cereda, Cristina Molecules Review Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline. MDPI 2020-11-18 /pmc/articles/PMC7698610/ /pubmed/33217959 http://dx.doi.org/10.3390/molecules25225389 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gagliardi, Stella
Morasso, Carlo
Stivaktakis, Polychronis
Pandini, Cecilia
Tinelli, Veronica
Tsatsakis, Aristides
Prosperi, Davide
Hickey, Miriam
Corsi, Fabio
Cereda, Cristina
Curcumin Formulations and Trials: What’s New in Neurological Diseases
title Curcumin Formulations and Trials: What’s New in Neurological Diseases
title_full Curcumin Formulations and Trials: What’s New in Neurological Diseases
title_fullStr Curcumin Formulations and Trials: What’s New in Neurological Diseases
title_full_unstemmed Curcumin Formulations and Trials: What’s New in Neurological Diseases
title_short Curcumin Formulations and Trials: What’s New in Neurological Diseases
title_sort curcumin formulations and trials: what’s new in neurological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698610/
https://www.ncbi.nlm.nih.gov/pubmed/33217959
http://dx.doi.org/10.3390/molecules25225389
work_keys_str_mv AT gagliardistella curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT morassocarlo curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT stivaktakispolychronis curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT pandinicecilia curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT tinelliveronica curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT tsatsakisaristides curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT prosperidavide curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT hickeymiriam curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT corsifabio curcuminformulationsandtrialswhatsnewinneurologicaldiseases
AT ceredacristina curcuminformulationsandtrialswhatsnewinneurologicaldiseases